Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

OnCusp Acquires Global Rights (ex-China) to CDH6 ADC from Multitude Therapeutics 

publication date: Jun 8, 2022

OnCusp Therapeutics, a New York-Shanghai biopharma, acquired global rights (ex-China) to a pre-clinical CDH6 antibody drug conjugate from Multitude Therapeutics. Multitude is a Shanghai-Redwood City antibody drug conjugate company that was spun out of Shanghai’s Abmart, which offers off-the-shelf and customized antibodies. OnCusp obtained rights to AMT-707, a highly differentiated second-in-class CDH6 (Cadherin-6 or K-cadherin) ADC. CDH6 is highly expressed in ovarian and renal cancers and also found in other malignancies. Multitude will receive upfront and milestone payments along with tiered royalties. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital